Management of transthyretin amyloidosis

Adalgisa Condoluci¹, Marie Théaudin², Rahel Schwotzer³, Aju P Pazhenkottil^{4

5}, Paolo Arosio⁶, Manuela Averaimo⁷, Ulrike Bacher⁸, Peter Bode⁹, Andrea Cavalli^{10

11}, Stefan Dirnhofer¹², Nadia Djerbi³, Stephan Dobner¹³, Thomas Fehr¹⁴, Maura Garofalo¹⁰, Ariana Gaspert⁹, Sabine Gerull¹⁵, Raphael Heimgartner¹⁴, Annemarie Hübers¹⁶, Hans H Jung¹⁷, Chiara Kessler¹, Raphael Knöpfel¹⁴, Natallia Laptseva⁴, Giulia Magini¹⁸, Robert Manka^{4

19}, Luca Mazzucchelli²⁰, Martin Meyer⁴, Violeta Mihaylova¹⁷, Pierre Monney²¹, Alessio Mylonas²², René Nkoulou²³, Thomas Pabst²⁴, Otmar Pfister²⁵, Axel Rüfer²⁶, Adrian Schmidt²⁷, Harald Seeger²⁸, Simon F Stämpfli²⁹, Guido Stirnimann³⁰, Thomas Suter¹³, Giorgio Treglia^{31

32

33}, Alexandar Tzankov¹², Friederike Vetter³, Markus Zweier³⁴, Andreas J Flammer⁴, Bernhard Gerber^{1

35}

Affiliations

¹ Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
² Department of Neurology, Neuromuscular Unit, University Hospital and University of Lausanne, Switzerland.
³ Department of Medical Oncology and Haematology, University Hospital of Zurich, Switzerland.
⁴ Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland.
⁵ Cardiac Imaging, Department of Nuclear Medicine, University Hospital and University of Zurich, Switzerland.
⁶ Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland.
⁷ Cardiocentro Ticino, Lugano, Switzerland.
⁸ Department of Haematology, Inselspital, University Hospital and University of Bern, Switzerland.
⁹ Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Switzerland.
¹⁰ Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
¹¹ Swiss Institute of Bioinformatics, Lausanne, Switzerland.
¹² Department of Medical Genetics and Pathology, University Hospital and University of Basel, Switzerland.
¹³ Department of Cardiology, Inselspital, University Hospital and University of Bern, Switzerland.
¹⁴ Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland.
¹⁵ Department of Hematology, Cantonal Hospital Aarau, Switzerland.
¹⁶ Department of Neurology, University Hospital and University of Geneva, Switzerland.
¹⁷ Department of Neurology, University Hospital and University Zurich, Switzerland.
¹⁸ Service de Transplantation, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
¹⁹ Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich,Switzerland.
²⁰ Cantonal Institute of Pathology, Locarno, Switzerland.
²¹ Department of Cardiology, University Hospital and University of Lausanne, Switzerland.
²² Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
²³ Department of Cardiology, University Hospital and University of Geneva, Switzerland.
²⁴ Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Switzerland.
²⁵ Department of Cardiology, University Hospital and University of Basel, Switzerland.
²⁶ Department of Haematology, Luzerner Kantonsspital, Lucerne, Switzerland.
²⁷ Department of Internal Medicine, Clinic for Medical Oncology and Haematology, City Hospital Waid and Triemli, Zurich, Switzerland.
²⁸ Department of Nephrology, University Hospital and University Zurich, Switzerland.
²⁹ Department of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.
³⁰ University Clinic for Visceral Surgery and Medicine, University Hospital Inselspital and University of Bern, Switzerland.
³¹ Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³² Department of Nuclear Medicine and Molecular Imaging, University Hospital and University of Lausanne, Switzerland.
³³ Faculty of Biomedical sciences, Università della Svizzera Italiana, Lugano, Switzerland.
³⁴ Institute of Medical Genetics, University of Zurich, Switzerland.
³⁵ University of Zurich, Switzerland.

PMID: 34694105
DOI: 10.4414/smw.2021.w30053

Free article

Management of transthyretin amyloidosis

Adalgisa Condoluci et al. Swiss Med Wkly. 2021.

Free article

. 2021 Oct 20:151:w30053.

doi: 10.4414/smw.2021.w30053. eCollection 2021 Oct 11.

Authors

Affiliations

¹ Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
² Department of Neurology, Neuromuscular Unit, University Hospital and University of Lausanne, Switzerland.
³ Department of Medical Oncology and Haematology, University Hospital of Zurich, Switzerland.
⁴ Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland.
⁵ Cardiac Imaging, Department of Nuclear Medicine, University Hospital and University of Zurich, Switzerland.
⁶ Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland.
⁷ Cardiocentro Ticino, Lugano, Switzerland.
⁸ Department of Haematology, Inselspital, University Hospital and University of Bern, Switzerland.
⁹ Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Switzerland.
¹⁰ Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
¹¹ Swiss Institute of Bioinformatics, Lausanne, Switzerland.
¹² Department of Medical Genetics and Pathology, University Hospital and University of Basel, Switzerland.
¹³ Department of Cardiology, Inselspital, University Hospital and University of Bern, Switzerland.
¹⁴ Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland.
¹⁵ Department of Hematology, Cantonal Hospital Aarau, Switzerland.
¹⁶ Department of Neurology, University Hospital and University of Geneva, Switzerland.
¹⁷ Department of Neurology, University Hospital and University Zurich, Switzerland.
¹⁸ Service de Transplantation, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
¹⁹ Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich,Switzerland.
²⁰ Cantonal Institute of Pathology, Locarno, Switzerland.
²¹ Department of Cardiology, University Hospital and University of Lausanne, Switzerland.
²² Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
²³ Department of Cardiology, University Hospital and University of Geneva, Switzerland.
²⁴ Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Switzerland.
²⁵ Department of Cardiology, University Hospital and University of Basel, Switzerland.
²⁶ Department of Haematology, Luzerner Kantonsspital, Lucerne, Switzerland.
²⁷ Department of Internal Medicine, Clinic for Medical Oncology and Haematology, City Hospital Waid and Triemli, Zurich, Switzerland.
²⁸ Department of Nephrology, University Hospital and University Zurich, Switzerland.
²⁹ Department of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.
³⁰ University Clinic for Visceral Surgery and Medicine, University Hospital Inselspital and University of Bern, Switzerland.
³¹ Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³² Department of Nuclear Medicine and Molecular Imaging, University Hospital and University of Lausanne, Switzerland.
³³ Faculty of Biomedical sciences, Università della Svizzera Italiana, Lugano, Switzerland.
³⁴ Institute of Medical Genetics, University of Zurich, Switzerland.
³⁵ University of Zurich, Switzerland.

PMID: 34694105
DOI: 10.4414/smw.2021.w30053

Erratum in

Erratum to: Management of transthyretin amyloidosis.
[No authors listed] [No authors listed] Swiss Med Wkly. 2021 Nov 4;151:w30104. doi: 10.4414/smw.2021.w30104. Swiss Med Wkly. 2021. PMID: 34846115 No abstract available.

Abstract

Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR amyloidosis have markedly improved in recent years. The first Swiss Amyloidosis Network (SAN) meeting (Zurich, Switzerland, January 2020) aimed to define a consensus statement regarding the diagnostic work-up and treatment for systemic amyloidosis, tailored to the Swiss healthcare system. A consortium of 45 clinicians and researchers from all Swiss regions and universities was selected by the SAN committee to represent all sub-specialty groups involved in care of patients with amyloidosis. A steering committee conducted the literature search and analysis, wrote the critical synthesis and elaborated a list of statements that were evaluated by all the participants. These recommendations will improve outcomes and quality of life for patients with ATTR amyloidosis. A global review of these guidelines is planned every 3 years with a formal meeting of all the involved experts.

PubMed Disclaimer

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of transthyretin amyloidosis

Affiliations

Management of transthyretin amyloidosis

Authors

Affiliations

Erratum in

Abstract

MeSH terms

Supplementary concepts

LinkOut - more resources

Full Text Sources

Research Materials